-
1
المؤلفون: Barjesteh van Waalwijk van Doorn-Khosrovani, Sahar, Taskén, Kjetil, F Haj Mohammad, Soemeya, Fagereng, Gro Live, Sørum Falk, Ragnhild, Helland, Åslaug, Jalkanen, Katriina, Edsjö, Anders, Russnes, Hege G, Steen Carlsson, Katarina, Ryll, Bettina, Lassen, Ulrik, Hallersjö Hult, Ebba, Lugowska, Iwona, Blay, Jean-Yves, Verlingue, Loic, Abel, Edvard, Lowery, Maeve A, Krebs, Matthew G, Staal Rohrberg, Kristoffer, Ojamaa, Kristiina, Oliveira, Julio, Verheul, Henk M W, Voest, Emile E, Gelderblom, Hans
المساهمون: PRIME-ROSE Consortium and the PCM4EU Consortium
المصدر: Acta Oncologica. 63:385-391
وصف الملف: electronic
-
2
المؤلفون: Taskén, Kjetil, Sørum Falk, Ragnhild, Helland, Åslaug, Fagereng, Gro Live, Abel, Edvard, Baltruskeviciene, Edita, Steen Carlsson, Katarina, Jalkanen, Katriina, Krebs, Matthew G, Lassen, Ulrik, Lowery, Maeve A, Ojamaa, Kristiina, Oliveira, Julio, Verlingue, Loic, Staal Rohrberg, Kristoffer, Ryll, Bettina, Barjesteh van Waalwijk van Doorn-Khosrovani, Sahar, Voest, Emile Eugene, Gelderblom, Hans, Verheul, Henk M W
المصدر: Journal of Clinical Oncology. 42(16)
-
3دورية أكاديمية
المؤلفون: Viller Tuxen, Ida, Barlebo Ahlborn, LiseAff1, Aff2, Mau-Soerensen, Morten, Staal Rohrberg, Kristoffer, Cilius Nielsen, Finn, Oestrup, Olga, Westmose Yde, Christina, Richter Vogelius, Ivan, Lassen, UlrikAff1
المصدر: British Journal of Cancer. 121(2):125-130
-
4دورية أكاديمية
لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل. -
5دورية أكاديمية
المؤلفون: Taskén K; Institute for Cancer Research, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Oslo, Norway. kjetil.tasken@medisin.uio.no., F Haj Mohammad S; Department of Medical Oncology, Leiden University Medical Centre, Leiden, The Netherlands. s.f.haj_mohammad@lumc.nl., Fagereng GL; Institute for Cancer Research, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Oslo, Norway. gfageren@ous-hf.no., Sørum Falk R; Oslo Centre for Biostatistics and Epidemiology, Oslo University Hospital, Oslo, Norway. rs@ous-hf.no., Helland Å; Institute for Cancer Research, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway. aslaug.helland@medisin.uio.no., Barjesteh van Waalwijk van Doorn-Khosrovani S; Department of Medical Oncology, Leiden University Medical Centre, Leiden, The Netherlands; CZ Health Insurance, Tilburg, The Netherlands. sahar.van.waalwijk@cz.nl., Steen Carlsson K; Swedish Institute for Health Economics, Lund, Sweden. katarina.steen_carlsson@ihe.se., Ryll B; Stockholm School of Economics Institute for Research, Stockholm, Sweden. Bettina.Ryll@hhs.se., Jalkanen K; Clinical Trial Unit, Comprehensive Cancer Centre, Helsinki University Hospital, Helsinki, Finland. katriina.jalkanen@hus.fi., Edsjö A; Department of Clinical Genetics, Pathology and Molecular Diagnostics, Region Skåne, Malmö, Sweden. anders.edsjo@skane.se., Russnes HG; Institute for Cancer Research, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Department of Pathology, Oslo University Hospital, Oslo, Norway. h.e.g.russnes@medisin.uio.no., Lassen U; Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. ulrik.lassen@regionh.dk., Hallersjö Hult E; Stockholm School of Economics Institute for Research, Stockholm, Sweden. ebba.hallersjo.hult@hhs.se., Lugowska I; Maria Sklodowska-Curie Institute of Oncology, Warsaw, Poland. Iwona.Lugowska@nio.gov.pl., Blay JY; Centre Léon Bérard, Lyon, France. jean-yves.blay@lyon.unicancer.fr., Verlingue L; Centre Léon Bérard, Lyon, France. Loic.VERLINGUE@lyon.unicancer.fr., Abel E; Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden; Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden. edvard.abel@vgregion.se., Lowery MA; Trinity St James Cancer Institute, Trinity College, Dublin, Ireland. MLOWERY@tcd.ie., Krebs MG; Division of Cancer Sciences, The University of Manchester and The Christie NHS Foundation Trust, Manchester, UK. matthew.krebs@nhs.net., Staal Rohrberg K; Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. kristoffer.staal.rohrberg@regionh.dk., Ojamaa K; Hematology-Oncology Clinic at Tartu University Hospital, Tartu, Estonia. Kristiina.Ojamaa@kliinikum.ee., Oliveira J; Instituto Português de Oncologia do Porto FG, Porto, Portugal. julio.oliveira@ipoporto.min-saude.pt., Verheul HMW; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. h.verheul@erasmusmc.nl., Voest EE; Department of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands. e.voest@nki.nl., Gelderblom H; Department of Medical Oncology, Leiden University Medical Centre, Leiden, The Netherlands. a.j.gelderblom@lumc.nl.
مؤلفون مشاركون: PRIME-ROSE Consortium and the PCM4EU Consortium
المصدر: Acta oncologica (Stockholm, Sweden) [Acta Oncol] 2024 May 23; Vol. 63, pp. 385-391. Date of Electronic Publication: 2024 May 23.
نوع المنشور: Journal Article
بيانات الدورية: Publisher: Medical Journals Sweden AB Country of Publication: Sweden NLM ID: 8709065 Publication Model: Electronic Cited Medium: Internet ISSN: 1651-226X (Electronic) Linking ISSN: 0284186X NLM ISO Abbreviation: Acta Oncol Subsets: MEDLINE
مواضيع طبية MeSH: Precision Medicine*/methods , Neoplasms*/therapy, Humans ; Europe ; European Union ; Drug Repositioning ; Clinical Trials as Topic/organization & administration